HB Wealth Management LLC Has $45.30 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Key Points

• HB Wealth Management LLC increased its stake in Johnson & Johnson by 31.6% during the 1st quarter, owning 273,134 shares valued at approximately $45.3 million.
• Johnson & Johnson's recent earnings report revealed a quarterly EPS of $2.77, surpassing analysts' expectations, with revenue of $23.74 billion.
• The company declared a quarterly dividend of $1.30 per share, representing an annualized dividend yield of 3.09%.

HB Wealth Management LLC increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 31.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 273,134 shares of the company's stock after buying an additional 65,655 shares during the period. HB Wealth Management LLC's holdings in Johnson & Johnson were worth $45,297,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Brighton Jones LLC grew its position in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Hudson Value Partners LLC raised its stake in Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after acquiring an additional 1,022 shares in the last quarter. Segall Bryant & Hamill LLC boosted its position in Johnson & Johnson by 1.0% during the 4th quarter. Segall Bryant & Hamill LLC now owns 36,670 shares of the company's stock worth $5,303,000 after acquiring an additional 367 shares during the period. WINTON GROUP Ltd acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $279,000. Finally, New Age Alpha Advisors LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $665,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on JNJ. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Barclays lifted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Finally, Guggenheim reaffirmed a "neutral" rating and issued a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded down $0.10 during trading hours on Wednesday, reaching $168.01. 1,987,730 shares of the company's stock were exchanged, compared to its average volume of 9,034,078. The business has a fifty day moving average price of $156.65 and a 200-day moving average price of $156.22. The stock has a market capitalization of $404.23 billion, a P/E ratio of 17.97, a P/E/G ratio of 2.12 and a beta of 0.41. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company's revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company posted $2.82 EPS. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.10%. Johnson & Johnson's payout ratio is 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.